English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: -31.22%
Price change 2019 → 2020: 193.47%
Price change 2020 → 2021: 147.22%
Price change 2021 → 2022: -29.57%
Price change 2022 → 2023: -25.09%
Price change 2023 → 2024: -7.75%
Price change 2024 → 2025: 218.49%
Price change 2025 → 2026: -48.02%
Price change 2026 (year to date): -49.74%
Financial growth
Revenue CAGR (8 years): 56.85%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.89
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -7.46
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 49.62% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| ABIONYX Pharma S.A. | – | 0.89 | – | 🔒 |
| Cellectis S.A. | – | 1.20 | +8.9 % | – |
| Euroapi S.A. | – | 0.08 | −1.3 % | – |
| Adocia S.A. | – | 5.97 | +18.8 % | – |
| Fermentalg | – | 0.20 | +38.5 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|